Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Sarah B. Rutter

2 papers in the library · 1 citation · publishing 2021-2025

Papers

Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence

medRxiv Preprint Server April 10, 2021 Agnes Norbury, Sarah B. Rutter, Abigail B. Collins et al. 1 citation preprint

In a small randomized clinical trial, repeated doses of ketamine improved PTSD symptoms more than midazolam. Brain scans showed that symptom improvement was linked to increased communication between the ventromedial prefrontal cortex and amygdala when viewing emotional faces, especially in those who received ketamine. Ketamine-related improvement was also predicted by decreased activity in the dorsal anterior cingulate during emotional conflict and increased resting-state connectivity between the ventromedial prefrontal cortex and anterior insula. Further analysis indicated that ketamine specifically strengthened the prefrontal cortex's ability to inhibit amygdala responses to threatening social cues, suggesting a normalization of brain circuits involved in fear regulation.

DOI: 10.1101/2021.04.10.21255127 (opens in new tab) Full text (opens in new tab) PTSD Post-traumatic stress disorder Psychedelic therapy Mental health condition +14

Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial.

The Journal of Clinical Psychiatry April 2, 2025 Adriana Feder, Oneysha Brown, Sarah B. Rutter et al.

Combining six ketamine infusions with a brief exposure-based psychotherapy, written exposure therapy (WET), produced large and durable reductions in PTSD symptoms for patients with chronic, severe PTSD. In an open-label trial, 13 of 14 patients completed treatment. PTSD symptom severity, measured by the CAPS-5, dropped from an average of 41.6 before treatment to 20.8 at 12 weeks, a large-magnitude improvement. Nine patients (69%) were treatment responders, and eight (61.5%) maintained improvement up to six months. The authors suggest the combined treatment may be effective but call for larger randomized controlled trials to confirm efficacy and synergy.

DOI: 10.4088/JCP.24m15622 (opens in new tab) Full text (opens in new tab) PTSD-Treatment Psychedelic-therapy Ketamine-therapy Mental-health-research